Reduction of nosocomial pneumonia after major burns by trace element supplementation: aggregation of two randomised trials by Berger,  M. M. et al.
Available online http://ccforum.com/content/10/6/R153Open AccessVol 10 No 6Research
Reduction of nosocomial pneumonia after major burns by trace 
element supplementation: aggregation of two randomised trials
Mette M Berger1, Philippe Eggimann1, Daren K Heyland2, René L Chioléro1, Jean-Pierre Revelly1, 
Andrew Day2, Wassim Raffoul3 and Alan Shenkin4
1Department of Adult Intensive Care Medicine & Burn Centre, Centre Hospitalier Universitaire Vaudois (CHUV), Rue du Bugnon 46, 1011 Lausanne, 
Switzerland
2Clinical Evaluation Research Unit, Kingston General Hospital, 76 Stuart Street, K7L 2V7 Kingston, Ontario, Canada
3Plastic and Reconstructive Surgery, Department of Surgery, CHUV, Rue du Bugnon 46, 1011 Lausanne, Switzerland
4Department of Clinical Chemistry, University of Liverpool, Duncan Building, Daulby Street, L69 3GA Liverpool, UK
Corresponding author: Mette M Berger, Mette.Berger@chuv.ch
Received: 16 Aug 2006 Revisions requested: 12 Sep 2006 Revisions received: 22 Sep 2006 Accepted: 2 Nov 2006 Published: 2 Nov 2006
Critical Care 2006, 10:R153 (doi:10.1186/cc5084)
This article is online at: http://ccforum.com/content/10/6/R153
© 2006 Berger et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Nosocomial pneumonia is a major source of
morbidity and mortality after severe burns. Burned patients
suffer trace element deficiencies and depressed antioxidant and
immune defences. This study aimed at determining the effect of
trace element supplementation on nosocomial or intensive care
unit (ICU)-acquired pneumonia.
Methods Two consecutive, randomised, double-blinded,
supplementation studies including two homogeneous groups of
41 severely burned patients (20 placebo and 21 intervention)
admitted to the burn centre of a university hospital were
combined. Intervention consisted of intravenous trace element
supplements (copper 2.5 to 3.1 mg/day, selenium 315 to 380
μg/day, and zinc 26.2 to 31.4 mg/day) for 8 to 21 days versus
placebo. Endpoints were infections during the first 30 days
(predefined criteria for pneumonia, bacteraemia, wound, urine,
and other), wound healing, and length of ICU stay. Plasma and
skin (study 2) concentrations of selenium and zinc were
determined on days 3, 10, and 20.
Results The patients, 42 ± 15 years old, were burned on 46%
± 19% of body surface: the combined characteristics of the
patients did not differ between the groups. Plasma trace
element concentrations and antioxidative capacity were
significantly enhanced with normalisation of plasma selenium,
zinc, and glutathione peroxidase concentrations in plasma and
skin in the trace element-supplemented group. A significant
reduction in number of infections was observed in the
supplemented patients, which decreased from 3.5 ± 1.2 to 2.0
± 1.0 episodes per patient in placebo group (p < 0.001). This
was related to a reduction of nosocomial pneumonia, which
occurred in 16 (80%) patients versus seven (33%) patients,
respectively (p < 0.001), and of ventilator-associated
pneumonia from 13 to six episodes, respectively (p = 0.023).
Conclusion Enhancing trace element status and antioxidant
defences by selenium, zinc, and copper supplementation was
associated with a decrease of nosocomial pneumonia in
critically ill, severely burned patients.
Introduction
Although the incidence of non-pulmonary infections has
decreased in severely burned patients [1], nosocomial pneu-
monia, including ventilator-associated pneumonia (VAP),
remains an important cause of morbidity and mortality [2,3].
During critical illness, oxidative stress is proportional to the
severity of the condition [4] and is particularly marked in
burned patients [5,6]. Patients with major burns suffer acute
early trace element depletion caused by the large exudative
trace element losses (selenium, copper, and zinc), which per-
sist until wound closure [7]. Oxidative stress is worsened by
these trace element deficiencies, particularly of selenium,
which is essential for activity of glutathione peroxidase
(GSHPx), a major antioxidant selenoenzyme among seleno-
proteins [8]. Selenium and zinc deficiencies have also been
linked to impaired immune response, and one underlying
mechanism is probably the inactivation of GSHPx [9]. DuringPage 1 of 8
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consequence of activation of the inflammation cascades [10].
The pathophysiology of VAP includes, among other factors,
impaired host-defence mechanisms [1,11]. A series of studies
suggest that correcting trace element deficiencies and
enhancing the antioxidant capacity in critically ill patients by
trace element supplementation reduce morbidity [12,13]. A
recent meta-analysis of 11 trials suggested that selenium sup-
plementation is associated with better clinical outcome and a
reduction of intensive care unit (ICU) mortality [14].
We conducted two consecutive randomised trials of trace ele-
ment supplementation in severely burned patients [15,16]
after having demonstrated large exudative losses of these
trace elements [7,17]. The purpose of the first study was to
investigate the impact of trace element supplements on overall
morbidity and on immune function, while monitoring the
plasma concentration [15]. In 20 patients, pulmonary infec-
tions during the first 30 days were apparently reduced, with an
improved immune response and an associated reduction of
length of stay normalised for percentage of burned body sur-
face area (BSA). The second study was similar in design but
focused on wound healing and tissue levels of the trace ele-
ments and antioxidant enzymatic activity [16]. We observed a
reduction of pulmonary infectious complications, a normalisa-
tion of plasma GSHPx activity, increased tissue selenium and
zinc concentrations, an improved wound healing, and a similar
reduction of normalised length of stay.
However, neither trial was adequately powered to analyse
nosocomial infections. The present study combines the data
from the two trials and explores the effect of trace element
supplementation on nosocomial (or ICU-acquired) pneumonia.
Materials and methods
Study design
Two prospective, randomised, double-blind, placebo-control-
led, trace element (copper, selenium, and zinc) supplementa-
tion studies were conducted consecutively at the burn unit of
the department of adult critical care medicine (ICU) in a tertiary
university hospital (Centre Hospitalier Universitaire Vaudois
[CHUV], Lausanne, Switzerland). Study periods were from
1993 to 1996 and from 1998 to 2003. The two trials were
aggregated: although infectious endpoints were identical,
their metabolic endpoints differed slightly (Table 1). The ethi-
cal committee approved both studies, and written informed
consent was obtained from the patients or their next-of-kin.
Patient population
Inclusion criteria were thermal burns involving more than 20%
of BSA in patients who were 16 to 65 years old. Patients with
chronic renal failure (creatinine >150 μmol/l), chronic liver dis-
ease with liver insufficiency, pregnancy, morbid obesity (body
mass index >35), or imminent death (do-not-resuscitate
orders within 48 hours of injury) were excluded.
Supplement administration
The patients were randomly assigned within 12 hours of
admission to receive either trace element supplements or pla-
cebo by a central intravenous line: the patients were allocated
to the treatments using a random list with a block size of 4. The
trace elements were provided as sodium selenite, copper glu-
conate (provided as powder), and zinc gluconate (Selenite®,
Zinc®, Nonan®; Laboratoires Aguettant, Lyon, France). Blind-
ing was carried out by the CHUV pharmacist, and the trace
element or saline solutions were undetectable on inspection
(colour, labelling). Patients, nurses, doctors, and investigators
were blinded.
Outcome measures
The objectives of these two studies regarding infectious com-
plications were identical. Infectious complications were pro-
spectively surveyed during the first 30 days after admission by
a trained research nurse and validated by an investigator
before unblinding (MMB). The type and the time of onset of
infections according to predefined criteria (see below) were
evaluated and recorded [18], as were the type, the timing, and
the reason for administration of all antimicrobial agents.
Specific variables of burn severity (total burned BSA, inhala-
tion injury, and Ryan score) [19], demographic data, length of
mechanical ventilation, and length of ICU stay were recorded.
Length of ICU stay is reported as days per percentage of BSA
burned. Severity of the initial condition was assessed by SAPS
II (Simplified Acute Physiology Score) [20]. Blood samples
were collected according to the primary endpoints. In the sec-
ond trial, skin biopsies were collected. Copper, zinc, and sele-
nium in plasma, and zinc and selenium in skin were determined
in duplicate by inductively coupled plasma mass spectrometry
(Plasmaquad 3 Inductively Coupled Plasma Mass Sectrome-
try (ICP-MS); VG Elemental, Winsford, Cheshire, UK). Plasma
GSHPx was determined by the Ransel method (Randox Labo-
ratories Ltd., Belfast, UK).
Pneumonia was defined as the combination of systemic
inflammatory response syndrome (SIRS) (temperature >38°C,
tachycardia, and leucocyte count >12,000 cells per mm3) with
a new infiltrate on the chest radiograph (or progression of an
existing infiltrate), a new or persisting hypoxaemia (partial pres-
sure of oxygen [PaO2] <70 mmHg with air or PaO2/FiO2 [frac-
tion of inspired oxygen] ratio <200), and purulent sputum or
tracheal secretion. Microbial confirmation, obtained by culture
of bronchoscopic bronchoalveolar lavage (BAL) or blind non-
bronchoscopic mini-BAL, was required in all mechanically ven-
tilated patients. Pneumonia occurring during the first 48 hours
was considered as community- or trauma-acquired and also to
be less susceptible to benefit from the supplementation and
was scored as early pneumonia [21]. Nosocomial pneumonia
was defined as a pneumonia occurring 48 hours or more after
admission. VAP was a nosocomial pneumonia acquired morePage 2 of 8
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ical ventilation.
Statistical analysis
Data from both trials were aggregated based on similarity of
supplementation and on identical surveillance methods of the
infectious complications. Patient characteristics were com-
pared between studies by the t test for continuous variables
and by the Fisher exact test for categorical variables. All other
analyses were stratified by study. The Mantel-Haenszel test
was used to compare binary variables, the exact stratified
Cochran-Armitage trend test was used to compare the
number of infections per patient, and the stratified log-rank test
was used to compare time-to-event and duration variables. All
time-to-event (duration) variables are presented as medians
with ranges, and a Kaplan-Meier curve is presented to com-
pare time to first episode of nosocomial pneumonia between
groups.
Results
Forty-one patients, 42 ± 15 years old, who were burned on
46% ± 19% of BSA were included (Table 2). The character-
Table 1
Comparative methods and endpoints of the two supplementation studies
Study 1 [15] Study 2 [16]
Methods
Study design Prospective, randomised, placebo-controlled 
trial
Prospective, randomised, placebo-controlled 
trial
Stratification None Age (≥ or <50 years)
Inhalation (yes/no)
Burned BSA (≥ or <50%)
Inclusion and exclusion criteria Identical Identical
Trace elements per day (intravenous) Copper 40.4 μmol (2.5 mg)/day
Selenium 2.9 μmol (315 μg)/day
Zinc 407 μmol (26.2 mg)/day
Copper 47.6 μmol (3.1 mg)/day
Selenium 4.8 μmol (380 μg)/day
Zinc 574 μmol (31.4 mg)/day
Duration of supplementation 8 days 14 days if burns <60% of BSA
21 days if burns ≥60% of BSA
Nutritional management Early enteral feeding (within 12 hours of 
admission) targeted at 1.3 times of resting 
energy expenditure, reached during a period of 
4 days
Identical
Vitamins per day Vitamin C 1 g, vitamin E 100 mg, vitamin B 
100 mg, and multivitamin (Cernevit®; Baxter, 
Plessis, France)
Identical
Blood sampling Days 0, 1, 5, 10, 15, 20, and 30 for plasma 
trace elements + vitamin dosages
Identical + plasma GSHPx activity
Skin biopsies None Days 3, 10, and 20: tissue selenium, zinc, and 
GSHPx activity
Endpoints
Clinical endpoints Length of mechanical ventilation
Length of ICU stay
Length of ICU stay per burned percentage of 
BSA
Identical
Wound healing Success of skin grafting (percentage of 
grafted area per percentage of area with 
surgical burns)
Identical + Whole body turnover of glycerol, 
glucose, and phenylalanine Phenylalanine skin 
incorporation
Immune response Chemotaxis capacity of neutrophil
T lymphocyte and neutrophil counts
Cell surface markers on lymphocytes
Adhesion molecules on neutrophils
Not performed
Infectious complications and definition Prospective surveillance during the first 30 
days of stay according to predefined criteria 
[18]
Identical
Antibiotic treatment Details on antibiotic delivery (type, dose, and 
route)
Identical
BSA, body surface area; GSHPx, glutathione peroxidase; ICU, intensive care unit.Page 3 of 8
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initial need for supporting organ failures, were similar across
studies and between the supplementation (n = 21) and pla-
cebo (n = 20) recipients in each study. Plasma selenium and
GSHPx concentrations were normalised and significantly
higher in the supplemented patients after day five, and plasma
zinc was higher from day ten, as were the skin selenium and
zinc concentrations on day 20 (p < 0.02).
Among clinical endpoints (Table 3), mortality and requirement
for mechanical ventilation did not differ significantly. The
number of days of antibiotherapy was significantly lower in the
supplemented group (p = 0.021). The length of stay was sig-
nificantly reduced in the supplemented patients, with a median
of 0.63 days versus 0.99 days per percentage of burned BSA
(p = 0.002).
All patients presented at least one episode of infection (Table
4). However, the number of infectious complications was
lower in the supplemented group, this decrease being due to
a lower number of nosocomial pneumonias (a mean of 0.33
episodes per patient in the supplemented group versus 1.55
episodes per patient in the placebo group, p < 0.001; Table
4). The difference remained significant when only the first epi-
sode of nosocomial pneumonia was considered (Figure 1).
VAP was also significantly less frequent (p = 0.001). Finally, in
the supplemented group, significantly fewer patients experi-
enced recurrent pneumonia (that is, new distinct pneumonia
with different microorganisms and new pulmonary infiltrates
occurring after a first episode whether early or nosocomial).
Wound, bloodstream, and urinary infections did not differ
between the groups.
Discussion
Our data show a marked and significant reduction in nosoco-
mial pneumonia and VAP in a cohort of severely burned
patients in whom trace element supplementation enhanced
the antioxidant defences. Indeed, plasma selenium and
GSHPx concentrations were significantly higher in the supple-
mented group after day five, as was zinc after day 10 [15,16].
VAP has been shown to be associated with early oxidative
stress as assessed by a decline in GSHPx activity in the
plasma and in the alveolar fluid [10]. Indeed, selenium is
essential for the activity of the various types of GSHPx, and
restoring selenium plasma concentrations has been shown to
restore their activity and the antioxidant status [8,22]. It has
also been suggested that, in critically ill patients with severe
SIRS, selenium supplementation may prevent acute renal fail-
ure because oxidative stress is implicated in its pathophysiol-
ogy [12]. In addition, trace element supplementation is likely to
improve neutrophil, macrophage, and lymphocyte function in
severely burned patients; in truth, we observed higher neu-
trophil counts in the supplemented patients of the first trial
[15]. Therefore, the reinforcement of antioxidant and metabolic
status by trace element supplementation is a likely underlying
pathophysiologic mechanism, explaining the prevention of
nosocomial pneumonia we observed in the supplemented
patients.
There are some limitations to the interpretation of these
results. There are minor differences between the designs of
the two studies we merged: (a) doses of and length of admin-
istration of supplements of selenium, of copper, and of zinc
were higher in the second trial, (b) the primary metabolic and
Table 2
Patient characteristics
Study 1 Study 2 Study 1 versus 
Study 2
(n = 20) (n = 21)
Supplemented 
group
Placebo group Total Supplemented 
group
Placebo group Total P valuea
(n = 10) (n = 10) (n = 20) (n = 11) (n = 10) (n = 21)
Age (years) 39.4 ± 15.8 42.6 ± 13.9 41.0 ± 14.6 46.3 ± 15.2 38.4 ± 16.2 42.5 ± 15.8 0.75
Burned BSA 
percentage
51.5 ± 22.5 44.9 ± 9.7 48.2 ± 17.2. 44.9 ± 22.3 44.3 ± 20.2 44.6 ± 20.8 0.55
Inhalation injury 2 (20%) 5 (50%) 7 (35%) 5 (46%) 4 (40%) 9 (43%) 0.75
SAPS II score 29.0 ± 6.4 27.2 ± 10.0 28.1 ± 8.3 34.3 ± 8.2 32.4 ± 9.3 33.4 ± 8.6 0.052
Ryan score 0.9 ± 0.8 1.0 ± 0.8 1.0 ± 0.8 1.1 ± 1.0 0.9 ± 0.7 1.0 ± 0.9 0.85
Patients on 
mechanical 
ventilation for 
>24 hours
8 (80%) 8 (80%) 16 (80%) 10 (90%) 9 (90%) 19 (90%) 0.34
aStudies compared by independent t test for continuous data and Fisher exact test for categorical data. BSA, body surface area; SAPS II, 
Simplified Acute Physiology Score.Page 4 of 8
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were consecutive in time, which might have been associated
with modest changes in general therapeutic procedures, and
(d) despite the highly significant results, the number of
patients was low. Aggregation of the data may therefore be
criticised, even though the characteristics of the patients were
similar in both studies and were well-balanced across treat-
ment arms. However, both studies were double-blind, pla-
cebo-controlled, and explored the same therapeutic concepts.
In addition, the type of infection surveillance, including defini-
tions for infectious complications, was identical. Accordingly,
the differences are unlikely to have significantly influenced the
rate of infectious complications.
The absence of impact on cutaneous infections raises ques-
tions. Why was the lung protected while the skin was not? Var-
ious hypotheses may explain this difference. First, because the
intravenous infusion of the supplements in a central venous
line will first pass through the lung, the concentrations of trace
elements could be higher in the lung than in the skin; this
hypothesis is supported by the delayed increase of the sele-
nium content of the skin. Indeed, in the biopsies of the burned
skin, selenium and zinc concentrations were similar in both
groups on days three and ten and increased significantly on
day 20 in the supplemented patients [16]. The values on day
20 correspond to a normalisation of skin content compared
with healthy volunteers (unpublished data), suggesting that
Table 4
Infectious complications
Type of infection Supplemented group (n = 21)
Number of patients per number of episodes 
(mean episodes ± SD per patient)
Placebo group (n = 20)
Number of patients per number of episodes 
(mean episodes ± SD per patient)
P valuea
Any infection 21/43 (2.0 ± 1.0) 20/69 (3.5 ± 1.2) <0.001
Pneumonia
Any 11/13 (0.6 ± 0.7) 20/35 (1.7 ± 1.1) 0.001
Early (0 to 48 hours) 6/6 (0.3 ± 0.5) 4/4 (0.2 ± 0.5) ns to 0.220
Nosocomial (>48 hours) 7/7 (0.33 ± 0.5) 16/31 (1.55 ± 1.0) <0.001
VAPb 6/6 (0.33 ± 0.5) 13/13 (0.65 ± 0.5) 0.023
Recurrentc 2/2 (0.1 ± 0.3) 13/19 (0.95 ± 0.8) <0.001
Skin and soft tissue infection 14/20 (0.95 ± 0.9) 14/19 (0.95 ± 0.8) ns to 0.871
Urinary tract infection 3/4 (0.2 ± 0.5) 4/5 (0.253 ± 0.6) ns to 0.726
Bloodstream infection 6/6 (0.3 ± 0.5) 5/7 (0.35 ± 0.7) ns to 0.734
Other infectiond 0 4/4 (0.2 ± 0.4) ns to 0.031
aP values are generated from Cochran-Armitage trend test; bVAP reduced from 5.5 to 3.6 episodes per 1,000 ventilator days in supplemented 
patients; crecurrent pneumonia designates new distinct pneumonia occurring after a first episode of pneumonia (early or nosocomial); dincluding 
three cases of enterocolitis and one case of chondritis of the ear. NP, nosocomial pneumonia; ns, non-significant; SD, standard deviation; VAP, 
ventilator-associated pneumonia.
Table 3
Clinical outcomes
Supplemented 
group,
Placebo group, P 
valuea
median (range) median (range)
Length of mechanical ventilation (days) 5 (0 to 28) 12 (0 to 28) 0.28
Length of antibiotherapy (days) 13 (3 to 30) 20 (6 to 29) 0.021
Length of ICU stay (days) 28 (9 to 151) 39 (16 to 145) 0.18
Length of ICU stay per proportion of burned BSA (days per percentage of BSA) 0.63 (0.23 to 1.64) 0.99 (0.43 to 2.48) 0.002
Mortality 2 out of 21 1 out of 20 0.57
aBy stratified log-rank test. BSA, body surface area; ICU, intensive care unit.Page 5 of 8
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two to three weeks. Second, the pathophysiology of pneumo-
nia may differ from that of skin infections.
Patients with major burns differ from other critically ill patients
in that the magnitude of their early exudative trace element
losses causes negative balances [7,17] and early deficiencies
involving copper, iron, selenium, manganese, and zinc. Such
deficiencies have been described recurrently since the 1960s
[13,23]. Copper is involved in wound healing (essential for the
synthesis of collagen and elastin), immunity (neutrophil func-
tion and immunoglobulin synthesis), and antioxidant defences
(copper-zinc superoxide dismutase) [24]. Zinc is virtually uni-
versal, being involved and essential in nearly every step of
anabolism, tissue repair, immunity, endocrine system, and anti-
oxidation [13]. The doses provided by the supplements in our
two trials were calculated to provide a little more than substi-
tution. The benefit of the intervention is probably the result of
the three trace elements, and not of selenium only. Patients
with major burns further differ from other critically ill patients by
having lower mortality rates [19], with only three deaths occur-
ring among 41 patients (7.3%). Mortality attributable to VAP is
controversial though [25]. The mortality rate of critically ill
patients developing VAP may be more directly linked to the
underlying condition. This consideration may also apply to
burns; indeed, the observed mortality is exactly as predicted
by the Ryan score. In addition, combined trace element defi-
ciencies do contribute to altered immune defences in burns;
the triple-supplement addressed this particular condition.
Selenium deserves special consideration among the three ele-
ments. Animal studies have shown that pre-injury selenium
deficiency aggravates the oxidative stress caused by burn
injury [26]. In addition, an analogy can be found with other crit-
ical illnesses; low selenium status is present in nearly every
septic ICU patient [27]. Indeed, this may be specific to
Europe, a geographic area characterised by a suboptimal sele-
nium status in the general population [28,29], whereas other
trace elements are generally normal. Selenium deficiency is
aggravated by acute illness [27]. Therefore, part of our find-
ings may apply to other European critically ill patients, and
selenium supplementation may find a place in a multimodal
pneumonia prevention strategy, but this must be verified.
Conclusion
This aggregation study shows that trace element supplemen-
tation is associated with a significant reduction of pulmonary
infectious complications, mainly due to a reduction of nosoco-
mial pneumonia in critically ill, burned patients. This was asso-
ciated with a highly significant reduction of the length of ICU
stay normalised for burned BSA. The likely underlying mecha-
nism is a reinforcement of endogenous antioxidant defences.
The implications of this finding for the management of burned
patients are substantial; hence, a larger multicentre trial is
required to confirm this preventive effect and to explore its
applicability to other critical care conditions.
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